EXCLUSIVE: Jessica Alba (Trigger Warning) has inked a deal to join Emily Bader, Logan Lerman and Adeline Rudolph in Netflix‘s reboot of rom-com 13 Going on 30, sources tell Deadline.
Reps for Netflix declined comment. Alba’s role, and the sequel’s logline, are being kept under wraps. Jennifer Garner, who starred in the original film, is an exec producer on the sequel, which kicked off production in L.A. last month.
Released in 2004 by Columbia Pictures, 13 Going on 30 centers on a 13-year-old girl who magically wakes up as her 30-year-old self and must navigate adulthood while rediscovering who she really is.
Garner played the grown-up version of the character, starring opposite Mark Ruffalo in the beloved film from Gary Winick. After grossing around $96 million in theaters worldwide and achieving major success on home video, the film has endured for decades as a cultural touchstone, making a reboot inevitable. Amid development on this film, Garner recently exec produced a stage musical adaptation, directed by Andy Fickman, which world premiered at the Manchester Opera House last fall.
RELATED: The 62 Movies That Have Made More Than $1 Billion At The Global Box Office
Brett Haley, helmer of Netflix’s hit rom-com People We Meet on Vacation, is directing from a script by Hannah Marks (Mark, Mary, & Some Other People) with revisions by Flora Greeson (The Princess Diaries 3). Joe Roth and Jeff Kirschenbaum are producing for RK Films, with Garner exec producing alongside Donna Roth and Susan Arnold, Scott Hemming for Revolution Studios, Alyssa Altman for RK Films, Marks, Gina Matthews and Ted Gidlow.
Alba comes to the 13 Going on 30 reboot after exec producing and starring in Netflix’s hit thriller Trigger Warning, which debuted at No. 1 in 67 countries and has been viewed more than 91 million times globally. Other upcoming projects for the actress include Maserati: The Brothers with Al Pacino and Anthony Hopkins and Justin Chadwick’s The Mark. She inked with both CAA and Untitled Entertainment in recent months, as we first reported, and is also repped by Sloane, Offer, Weber & Dern.
